Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
J Neural Transm (Vienna). 2020 Feb;127(2):181-187. doi: 10.1007/s00702-020-02149-3. Epub 2020 Feb 5.
While the initial causes of Parkinson's disease (PD) are not clearly defined, iron deposition has long been implicated in the pathogenesis of PD. The substantia nigra of PD patients, where the selective loss of dopaminergic neurons occurs, show a fairly selective and significant elevation in iron contents. However, the question remains whether iron deposition represents the initiation cause or merely the consequence of nigral degeneration. Here, we describe existing findings regarding the interaction of iron with neuromelanin and alpha synuclein, the iron deposition in experimental animal model of PD and sporadic and familial PD patients, and the treatment option involving the use of iron chelators for targeting the aberration of iron level in brain. This review may provide us a better understanding of the role of iron in PD to address the question of cause or consequence.
虽然帕金森病(PD)的初始原因尚不清楚,但铁沉积长期以来一直被认为与 PD 的发病机制有关。在 PD 患者的黑质中,多巴胺能神经元选择性丧失,铁含量明显升高。然而,问题仍然是铁沉积是代表起始原因还是仅仅是黑质退化的结果。在这里,我们描述了关于铁与神经黑色素和α-突触核蛋白相互作用的现有发现,PD 的实验动物模型以及散发性和家族性 PD 患者的铁沉积,以及涉及使用铁螯合剂靶向大脑中铁水平异常的治疗选择。这篇综述可能使我们更好地了解铁在 PD 中的作用,以解决病因或结果的问题。